Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12963413 | 1.00 | ADK (0.33) | ADKPRMT5WDR77ADORA3ACHE | |
| SCHEMBL1737262 | 0.86 | XDH (0.39) | ADKPRMT5WDR77XDH | |
| SCHEMBL14378917 | 0.84 | ADK (0.39) | ADKPRMT5WDR77ADORA3METTL3 | |
| SCHEMBL13020659 | 0.84 | ADK (0.39) | ADKPRMT5WDR77ADORA3METTL3 | |
| SCHEMBL13104990 | 0.80 | ADK (0.30) | ADK | |
| SCHEMBL14378918 | 0.80 | ADK (0.30) | ADK | |
| SCHEMBL14378919 | 0.78 | GK (0.34) | — | |
| SCHEMBL14378921 | 0.77 | — | — | |
| SCHEMBL13064105 | 0.77 | PRKAB2 (0.39) | PRMT5WDR77ACHE | |
| SCHEMBL13020652 | 0.77 | PRKAB2 (0.39) | PRMT5WDR77ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | RNASEL, RNASE1, RNASEH1 | ADK 932/4885PRMT5 501/4885WDR77 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.